Christopher A. Klebanoff, M.D.

Memorial Sloan Kettering Cancer Center

Dr. Klebanoff is cellular immunologist and medical oncologist with 19 years of experience in the pre-clinical and clinical development of T cell-based immunotherapies for the treatment of solid and hematologic cancers. Prior to joining Memorial Sloan Kettering, he was an assistant clinical investigator and a NIH-Howard Hughes Medical Institute Research Scholar at the U.S. National Institutes of Health in Bethesda, MD. As a member of the NCI Surgery Branch’s senior staff, he participated in the early phase clinical development of numerous T cell-based therapies which would later be licensed to commercial entities. These include the anti-CD19 28z CAR that would become Yescarta, gene engineered TCR therapies targeting NY-ESO-1, MAGE-A3/6, and HPV E6, and neoantigen selected TIL therapies for a diverse range of solid cancers.

Dr. Klebanoff’s laboratory investigations have contributed to the mechanistic understanding of how lymphodepletion enhances adoptive immunotherapies and how T cell differentiation status influences cellular persistence and clinical outcomes.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.